- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06192758
Første i human dosiseskaleringsundersøgelse, der evaluerer sikkerheden ved TheraSphere prostatacancer (PCa)-enhed (VOYAGER)
En tidlig gennemførlighedsundersøgelse for at evaluere sikkerheden af TheraSphere prostatakræft (PCa)-enheden hos patienter med klinisk lokaliseret prostatakræft
The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
TheraSphere™ Y-90 Glass Microspheres are a targeted cancer therapy consisting of tiny glass beads containing radioactive Yttrium-90 (Y-90), which are injected directly into the blood vessel feeding the tumor through a microcatheter using advanced imaging guidance. The glass microspheres enter the tumor's blood supply, lodge within the blood vessels feeding the tumor, and release radiation to the tumor. The radiation works to destroy the tumor cells from within, thus limiting radiation exposure to surrounding normal tissues, a process referred to as selective internal radiation therapy (SIRT).
This study aims to investigate the maximum safe radiation dose of TheraSphere Prostate Cancer (PCa) device that can be delivered in patients with clinically localized prostate cancer. The study will also evaluate the full safety profile, technical feasibility, efficacy, and quality of life metrics of the TheraSphere PCa device.
Participants will be asked to complete the following:
- At least two image-guided visits, including a mapping assessment (without Technetium Tc albumin aggregated [Tc-MAA]) prior to treatment
- One treatment visit, including image-guided assessments
- Fifteen post-treatment follow-up visits for a total of approximately 20 visits over the 5-year study period
Note: the VOYAGER Study is a staged investigational device exemption (IDE) study; therefore, the full enrollment of 21 to 36 subjects is subject to FDA approval following safety review of the first 10 subjects enrolled.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern Memorial Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Subject has ability to comprehend and willingness to sign and date the IRB-approved study informed consent form (ICF), and to comply with the study testing, procedures, and follow-up schedule.
-
Histologic confirmation of adenocarcinoma of the prostate by MR-fusion biopsy. Referral biopsy for eligibility must be completed between 180 days and 6 weeks prior to mapping procedure.
-
Subject with favorable intermediate risk clinically localized prostate cancer defined per NCCN Guidelines version 3.2022 as follows:
-
Favorable intermediate-risk has all the following:
-
i. One Intermediate Risk Factor (IRF):
- cT2b-cT2c
- Grade Group 2 or 3
- PSA 10-20 ng/mL
-
ii. Grade Group 1 or 2
-
iii. <50% biopsy cores positive (e.g., <6 of 12 cores)
-
-
Staging MRI must confirm American Joint Committee on Cancer (AJCC, 8th edition) stage T1, T2a, T2b or T2c.
-
Whole prostate gland volume ≥ 60 cc (measured on MRI)
-
International Prostate Score Symptom (I-PSS) ≤ 18
-
Estimated life expectancy of >5 years according to NCCN guideline's tools (NCCN v03.2022) who has declined or is ineligible for Standard of Care treatments (observation, active surveillance, surgery, and radiation therapies [brachytherapy/external beam radiation therapy])
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
-
Angiographic inclusion criteria:
- a. Type I to IV prostate artery origins on both hemiglands.1
- b. No evidence of procedure limiting vascular abnormalities (aneurysms, stenosis, shunt, fistula, occlusion) or morphologic asymmetric single prostate artery on either side (hemigland)
- c. Bilaterally accessible solitary prostatic arteries.
- d. Complete perfusion of the prostate gland via a single dominant vessel for each hemigland
-
Have adequate organ and bone marrow function within 30 days prior to index procedure, as defined below:
- a. International Normalized Ratio (INR) ≤ 1.2 (in absence of anticoagulation)
- b. Platelets ≥ 75,000/L
- c. GFR ≥ 40 mL/min/1.73m2
- d. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
- e. Hemoglobin (Hgb) ≥ 9.0 g/dL (Note: the use of transfusion or other intervention to achieve adequate bone marrow function is acceptable
- f. ALT/AST ≤ 5 x upper limit of normal (ULN)
- g. Bilirubin ≤ 2 mg/dL
-
Patients with known Human Immunodeficiency Virus (HIV) infection are eligible with well controlled HIV infection, no current or previous AIDS-related complications and CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
Exclusion Criteria:
-
Direct evidence of regional or distant metastases after appropriate staging studies per NCCN guidelines (v03.2022)
-
Histological evidence of intraductal features
-
Previous treatments (pelvic radiotherapy, surgery, prostate artery embolization [PAE], transurethral resection of the prostate [TURP] or previous/ planned hormonal therapy
-
History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia, current gross haematuria, or current urinary catheter
-
Subjects with ongoing urinary tract infection, prostate abscess, prostatitis, or neurogenic bladder
-
Prior significant rectal surgery (haemorrhoidectomy is acceptable)
-
Prior invasive malignancy unless disease free for a minimum of 3 years. Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease
-
Hip prosthesis
-
Medical contraindication to undergo contrast-enhanced angiography, CT scan and magnetic resonance imaging (MRI), or arterial catheterization, or known history of hypersensitivity reactions to iodinated and gadolinium-based contrast product
-
Angiographic exclusion criteria:
- a. Perfusion to tissues outside the Planning Target Volume (PTV) that cannot be corrected by placement of the catheter distal to collateral vessels or the application of standard angiographic techniques, such as coil embolization
- b. Type V prostatic artery origin on either side
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: TheraSphere PCa Dose Escalation
Participants will be treated in cohorts of three across three sequential dose levels:
|
Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum tolerated radiation dose of TheraSphere PCa
Tidsramme: Through 90 days post-treatment
|
• The Maximum Tolerated Dose (MTD) of Yttrium-90 Glass Microspheres (TheraSphere™ PCa) is based on rate of dose limiting toxicity (DLT) through 90 days, defined as any ≥ grade 3 adverse event (AE) according to CTCAE v.5 |
Through 90 days post-treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events (AEs)
Tidsramme: Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
|
The following AEs/SAEs will be assessed in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0:
|
Through 5 years post-treatment (acute ≤ 90 days and late > 90 days)
|
|
Rate of success of delivering intended dose
Tidsramme: Immediately post-treatment
|
• The ability to deliver the intended TheraSphere PCa absorbed dose (+/- 20%) to the treatment volume based on post-treatment PET derived absorbed dose. |
Immediately post-treatment
|
|
Recurrence Free Survival
Tidsramme: Through 5 years post-treatment
|
• Biochemical Recurrence Free Survival (bRFS) based on PSA according to the Phoenix criteria (RTOG-ASTRO definition). Biochemical recurrence of prostate cancer after curative treatment is defined as a PSA rise of ≥ 2 ng/mL above the post-treatment nadir. |
Through 5 years post-treatment
|
|
Progression free survival (PFS)
Tidsramme: Through 5 years post-treatment
|
• Progression free survival (PFS) and local progression free survival (LPFS), defined as time from inclusion until one of the following events, whichever comes first: biochemical progression (Phoenix criteria) or clinical progression. |
Through 5 years post-treatment
|
|
Prostate cancer specific survival
Tidsramme: Through 5 years post-treatment
|
• Prostate cancer specific survival will be measured as the number of days between treatment with TheraSphere PCa and death by prostate cancer. |
Through 5 years post-treatment
|
|
Overall survival (OS)
Tidsramme: Through 5 years post-treatment
|
• OS will be measured as the number of days between treatment with TheraSphere PCa and death by any cause. |
Through 5 years post-treatment
|
|
Rate of subsequent prostate anticancer treatment
Tidsramme: Through 5 years post-treatment
|
• A summary table with number of subjects (%) who received subsequent definitive or systematic therapy and type of therapies received will be presented. |
Through 5 years post-treatment
|
|
Rate of histopathological recurrence
Tidsramme: Through 5 years post-treatment
|
• Rate of recurrence based on histopathological assessment of prostate MR/US-fusion biopsy in patients with evidence of progression. |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by EPIC-26
Tidsramme: Through 5 years post-treatment
|
• Change from baseline measured through Expanded Prostate Cancer Index Composite (EPIC-26). |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by MSHQ
Tidsramme: Through 5 years post-treatment
|
• Change from baseline measured through Male Sexual Health Questionnaire (MSHQ). |
Through 5 years post-treatment
|
|
Quality of Life (QoL) measured by I-PSS
Tidsramme: Through 5 years post-treatment
|
• Change from baseline measured through International Prostate Symptom Score (I-PSS). |
Through 5 years post-treatment
|
|
Maximum urinary flow (Qmax)
Tidsramme: Through 5 years post-treatment
|
• Change from baseline |
Through 5 years post-treatment
|
|
Post-void residual (PVR) urine test
Tidsramme: Through 5 years post-treatment
|
• Change from baseline |
Through 5 years post-treatment
|
|
Dose Distribution
Tidsramme: Through one-week post-treatment
|
• Dose Volume Histogram (DVH) and evaluation of D90 from post-treatment Y90 PET-MRI/CT. |
Through one-week post-treatment
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Prostatic imaging assessment
Tidsramme: Through 5 years post-treatment
|
• Qualitative analysis of multi-parametric MRI (mp-MRI) and PI-RADS score |
Through 5 years post-treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Samdeep Mouli, M.D., M.S., Northwestern Medical Hospital
- Ledende efterforsker: Mark Hurwitz, MD, Westchester Medical Center
Publikationer og nyttige links
Generelle publikationer
- Mouli SK, Raiter S, Harris K, Mylarapu A, Burks M, Li W, Gordon AC, Khan A, Matsumoto M, Bailey KL, Pasciak AS, Manupipatpong S, Weiss CR, Casalino D, Miller FH, Gates VL, Hohlastos E, Lewandowski RJ, Kim DH, Dreher MR, Salem R. Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation. J Vasc Interv Radiol. 2021 Aug;32(8):1103-1112.e12. doi: 10.1016/j.jvir.2021.01.282. Epub 2021 Apr 9.
- Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 Oct 15;24(20):4921-4930. doi: 10.1158/1078-0432.CCR-18-0246. Epub 2018 May 16.
- Meiselman S, Thomas MA, Giardina JD, Zheleznyak A, Thorek DLJ, Malone CD. Advances in Radioembolization for Liver Cancer. J Vasc Interv Radiol. 2025 Dec;36(12):1876-1881. doi: 10.1016/j.jvir.2025.07.018.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- S2493
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .